Hemoglobin Left-Shifting for Mitochondrial Oxygen Toxicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for mitochondrial-associated dysfunctions and diseases, such as Leigh syndrome and Friedreich's ataxia, are inadequate due to genetic heterogeneity and pleiotropy, with no proven efficacy in managing these disorders.

Innovation Solution

Administering therapeutically effective amounts of treatments that induce hemoglobin left-shifting and/or anemia, including small molecule allosteric effectors of hemoglobin (AEHs), inhaled carbon monoxide (CO), carbon monoxide-releasing molecules (CORMs), gene therapy for fetal hemoglobin expression, and bloodletting, to reduce oxygen delivery and alleviate mitochondrial dysfunction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for mitochondrial-associated dysfunctions, then genetic heterogeneity and pleiotropy are present, but treatment efficacy is insufficient

Engineering Contradiction:

Improvetreatment efficacyVSAvoidgenetic heterogeneity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the therapeutic parameter from targeting specific genetic mutations to modulating hemoglobin-oxygen dissociation curve position. By using allosteric effectors that shift the curve leftward, the treatment achieves universal efficacy across different mitochondrial diseases regardless of genetic heterogeneity, while the parameter change in oxygen affinity provides the therapeutic effect

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If oxygen delivery is reduced through hemoglobin left-shifting, then tissue oxygen toxicity is reduced, but oxygen delivery to tissues decreases

Engineering Contradiction:

Improvetissue oxygen toxicityVSAvoidoxygen delivery

Core Design Contradiction:

Object-affected harmful factorsVSUse of energy by moving object

Solution Approach 1:

The patent applies local quality by creating different oxygen delivery conditions in different tissue compartments. Hemoglobin left-shifting creates localized oxygen retention in circulation while tissues experience reduced oxygen toxicity. The effect is spatially differentiated between the vascular compartment (where oxygen is retained) and the tissue compartment (where oxygen toxicity is reduced)

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent inverts the conventional approach by instead of increasing oxygen delivery to treat mitochondrial dysfunction, it reduces oxygen delivery through hemoglobin left-shifting. This counterintuitive approach proves therapeutic by reducing oxidative stress and oxygen toxicity in tissues with already compromised mitochondrial function

Inventive Principle:

Principle #13The other way round (Inversion)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These interventions effectively lower brain oxygen levels, reversing or preventing neurological disease in mitochondrial disease models by reducing tissue oxygen toxicity, thereby improving survival and neurological function.

Implementation Method 1

inhaled carbon monoxide (CO)...increase the affinity of hemoglobin for oxygen

Methodology Applied

Scientific EffectCarbon monoxide binding to hemoglobin: Absorption (physical)

Implementation Method 2

small molecule Allosteric Effector of Hb (AEH) that left shifts Hb

Methodology Applied

Scientific EffectAllosteric modulation:

Data Source

PatentUS12544403B2Methods to treat mitochondrial-associated dysfunctions or diseases

Publication Date: 2026.02.10 THE GENERAL HOSPITAL CORP

AI summary

Methods for the treatment of disorders associated with mitochondrial dysfunction, including rare, inborn errors of metabolism caused by genetic mutations; neurodegenerative disease; diabetes; and aging and age-associated decline. Generally, the methods include administering a therapeutically effective amount of one or more treatments that (i) induce hemoglobin “left-shifting” and/or (ii) induce anemia, as described herein, to a subject who is in need of, or who has been determined to be in need of, such treatment.